The study found that men in their 40s and 50s with a baseline PSA at or above the median PSA were much more likely to undergo a biopsy and be diagnosed with low-risk prostate cancer. However, the majority of tumors (89 percent) found in both age groups were classified as “low risk.”
The study’s findings are being released soon after the U.S. Preventive Services Task Force published draft recommendations that the test may not save lives.
Related Articles on the Mayo Clinic:
Mayo Clinic Provides Guidance on Using Therapeutic Cooling for Sudden Cardiac Arrest
Mayo Clinic Partners With Researchers in India
Arizona’s Kingman Regional Joins Mayo Clinic Care Network
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
